This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2004 Nov;1(1):16-7.

doi: 10.1038/ncponc0023.

Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?

Jeffrey H Silber¹

Affiliations

PMID: 16264791
DOI: 10.1038/ncponc0023

Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?

Jeffrey H Silber. Nat Clin Pract Oncol. 2004 Nov.

. 2004 Nov;1(1):16-7.

doi: 10.1038/ncponc0023.

Author

Jeffrey H Silber¹

Affiliation

¹ Center for Outcomes Research, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. silber@email.CHOP.edu

PMID: 16264791
DOI: 10.1038/ncponc0023

No abstract available

PubMed Disclaimer

Similar articles

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. Lipshultz SE, et al. N Engl J Med. 2004 Jul 8;351(2):145-53. doi: 10.1056/NEJMoa035153. N Engl J Med. 2004. PMID: 15247354 Clinical Trial.
Doxorubicin-induced myocardial injury.
Fujisaki G, Inokuchi C, Murashige N. Fujisaki G, et al. N Engl J Med. 2004 Oct 28;351(18):1908-9; author reply 1908-9. doi: 10.1056/NEJM200410283511819. N Engl J Med. 2004. PMID: 15509827 No abstract available.
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Lipshultz SE, et al. Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. Epub 2010 Sep 16. Lancet Oncol. 2010. PMID: 20850381 Free PMC article. Clinical Trial.
Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE. Lipshultz SE. Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B. Anderson B. Pediatr Blood Cancer. 2005 Jun 15;44(7):584-8. doi: 10.1002/pbc.20358. Pediatr Blood Cancer. 2005. PMID: 15700251 Review.

See all similar articles

Cited by

Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway.
Zhang Y, Ma C, Liu C, Wei F. Zhang Y, et al. PeerJ. 2020 May 11;8:e8845. doi: 10.7717/peerj.8845. eCollection 2020. PeerJ. 2020. PMID: 32435528 Free PMC article.
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman AM, Yusuf SW, Ewer MS. Rahman AM, et al. Int J Nanomedicine. 2007;2(4):567-83. Int J Nanomedicine. 2007. PMID: 18203425 Free PMC article. Review.
Hyaluronic Acid-Modified and Doxorubicin-Loaded Gold Nanoparticles and Evaluation of Their Bioactivity.
Li LS, Ren B, Yang X, Cai ZC, Zhao XJ, Zhao MX. Li LS, et al. Pharmaceuticals (Basel). 2021 Jan 28;14(2):101. doi: 10.3390/ph14020101. Pharmaceuticals (Basel). 2021. PMID: 33525717 Free PMC article.
Primary Protection of Diosmin Against Doxorubicin Cardiotoxicity via Inhibiting Oxido-Inflammatory Stress and Apoptosis in Rats.
Abohashem RS, Ahmed HH, Sayed AH, Effat H. Abohashem RS, et al. Cell Biochem Biophys. 2024 Jun;82(2):1353-1366. doi: 10.1007/s12013-024-01289-7. Epub 2024 May 14. Cell Biochem Biophys. 2024. PMID: 38743136
Clinical Significance of Non-Coding RNA Regulation of Programmed Cell Death in Hepatocellular Carcinoma.
Chen W, Ruan M, Zou M, Liu F, Liu H. Chen W, et al. Cancers (Basel). 2023 Aug 21;15(16):4187. doi: 10.3390/cancers15164187. Cancers (Basel). 2023. PMID: 37627215 Free PMC article. Review.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information